Therefore, based on the results of many clinical trials, current guidelines recommend the first-line use of kinase inhibitors when treating unresectable lung cancers with mutations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1, BRAF, neurotrophic receptor tyrosine kinase 1/2/3 (NTRK1/2/3), or MET [1,2,3,4,5,6]. This evidence concerns the gene NTRK1 and lung cancer.